Average Co-Inventor Count = 5.82
ph-index = 17
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Abbott Laboratories Corporation (79 from 4,179 patents)
2. Global Blood Therapeutics, Inc. (5 from 57 patents)
3. Abbvie Inc. (3 from 822 patents)
4. Imago Pharmaceuticals, Inc. (3 from 5 patents)
5. Elan Pharmaceuticals, Inc. (1 from 202 patents)
6. Abbott Laboraotries (1 from 1 patent)
7. John W. Erickson (0 patent)
8. Perrigo Pharma International D.a.c. (0 patent)
9. Jacob J. Plattner (0 patent)
10. Daniel W. Norbeck (0 patent)
11. Dale J. Kempf (0 patent)
12. Lynn M. Codacovi (0 patent)
13. Hing L. Sham (0 patent)
92 patents:
1. 11584734 - Tricyclic compounds as histone methyltransferase inhibitors
2. 11014884 - Modulators of hemoglobin
3. 10144746 - Bridged bicyclic kallikrein inhibitors
4. 9815853 - Bridged bicyclic kallikrein inhibitors
5. 9796706 - Inhibitors of Jun N-terminal kinase
6. 9695166 - Pyrazolopyridine pyrazolopyrimidine and related compounds
7. 9493485 - Spirocyclic dihydro-thiazine and dihydro-oxazine BACE inhibitors, and compositions and uses thereof
8. 9073891 - Inhibitors of Jun N-terminal kinase
9. 8748627 - Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
10. 8735595 - Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
11. 8637546 - Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DDP-IV)
12. 8450363 - Inhibitors of Jun N-terminal kinase
13. 8207350 - Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
14. 8119664 - Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
15. 7968707 - Retroviral protease inhibiting compounds